Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer

NCT02125084 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Everolimus
DRUG: Enzalutamide

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]